Safety and Efficacy of AGN-199201 and AGN-190584 in Patients With Presbyopia
Phase of Trial: Phase II
Latest Information Update: 08 Dec 2015
Price : $35 *
At a glance
- Drugs AGN 190584 (Primary) ; Oxymetazoline (Primary)
- Indications Presbyopia
- Focus Therapeutic Use
- Sponsors Allergan
- 25 Jan 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 12 Aug 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 30 Jul 2014 New trial record